Cemsidomide Combo Passes First Safety Test in Phase 1b; Data Readout Slated for Mid-2027
CCCC sits 82% above its 52-week low of $1.69.
Summary
The Phase 1b trial of cemsidomide plus elranatamab has cleared its first safety cohort, with the 75 µg dose declared safe. The trial is advancing to dose escalation and expansion, and data from all cohorts are expected in mid-2027.
Key Events · Product Development and Regulatory · CCCC
-
75 µg Cemsidomide + Elranatamab Declared Safe
After the first cohort of six patients completed evaluation, the safety data review committee declared the 75 µg cemsidomide dose level in combination with elranatamab safe.
-
Phase 1b Trial Advances to Expansion and Escalation
Enrollment is now underway for a 75 µg expansion cohort and a 100 µg dose escalation safety cohort, with potential to expand at each dose level once declared safe.
-
Preliminary Biomarker Data Supports Combination Rationale
Data from the first two patients showed that cemsidomide drives CD8+ effector memory T cell expansion and activation (elevated HLA-DR) and prevents T-cell exhaustion (PD-1, TIM-3, LAG3 markers did not increase).
-
Phase 1b Data Readout Expected Mid-2027
Data from all cohorts evaluated in the Phase 1b trial are expected in mid-2027, with Phase 2 MOMENTUM initial ORR data expected in 2H 2027.
Analysis · CCCC · Life Sciences
The safety data review committee has cleared the 75 µg dose of cemsidomide in combination with elranatamab, enabling the Phase 1b trial to move into dose escalation and expansion cohorts. This marks the first safety validation of cemsidomide alongside a BCMA-directed bispecific antibody, a critical step toward positioning it as a backbone therapy in multiple myeloma. Preliminary biomarker data from the first two patients, showing T-cell activation and prevention of T-cell exhaustion, lends mechanistic support to the combination strategy. With a cash runway through 2028 as previously disclosed, the company has sufficient time to reach the mid-2027 data readout without immediate financing pressure.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CCCC was trading at $3.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $372.8M. The 52-week trading range was $1.69 to $5.17. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.